10,000 Shares in Sanofi (NASDAQ:SNY) Bought by Altshuler Shaham Ltd

Altshuler Shaham Ltd bought a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, Holdings Channel reports. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $482,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in Sanofi during the fourth quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Bessemer Group Inc. grew its stake in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in Sanofi in the fourth quarter worth $31,000. Finally, Sierra Ocean LLC acquired a new position in shares of Sanofi during the fourth quarter valued at $44,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday. They issued an “outperform” rating and a $65.00 price objective on the stock. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.33.

Sanofi Stock Performance

SNY opened at $50.56 on Thursday. The business has a 50 day moving average price of $54.83 and a two-hundred day moving average price of $52.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $127.73 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.